297 related articles for article (PubMed ID: 17269997)
1. Efficacy and safety of thalidomide in children and young adults with intractable inflammatory bowel disease: long-term results.
Lazzerini M; Martelossi S; Marchetti F; Scabar A; Bradaschia F; Ronfani L; Ventura A
Aliment Pharmacol Ther; 2007 Feb; 25(4):419-27. PubMed ID: 17269997
[TBL] [Abstract][Full Text] [Related]
2. Thalidomide in luminal and fistulizing Crohn's disease resistant to standard therapies.
Plamondon S; Ng SC; Kamm MA
Aliment Pharmacol Ther; 2007 Mar; 25(5):557-67. PubMed ID: 17305756
[TBL] [Abstract][Full Text] [Related]
3. Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506).
Fellermann K; Ludwig D; Stahl M; David-Walek T; Stange EF
Am J Gastroenterol; 1998 Oct; 93(10):1860-6. PubMed ID: 9772045
[TBL] [Abstract][Full Text] [Related]
4. 6-tioguanine monitoring in steroid-dependent patients with inflammatory bowel diseases receiving azathioprine.
Roblin X; Serre-Debeauvais F; Phelip JM; Faucheron JL; Hardy G; Chartier A; Helluwaert F; Bessard G; Bonaz B
Aliment Pharmacol Ther; 2005 Apr; 21(7):829-39. PubMed ID: 15801918
[TBL] [Abstract][Full Text] [Related]
5. A report on efficacy and safety of azathioprine in a group of inflammatory bowel disease patients in northwest Greece.
Christodoulou D; Katsanos K; Baltayannis G; Tzabouras N; Tsianos EV
Hepatogastroenterology; 2003; 50(52):1021-4. PubMed ID: 12845970
[TBL] [Abstract][Full Text] [Related]
6. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease--a long-term follow-up.
Baumgart DC; Pintoffl JP; Sturm A; Wiedenmann B; Dignass AU
Am J Gastroenterol; 2006 May; 101(5):1048-56. PubMed ID: 16573777
[TBL] [Abstract][Full Text] [Related]
7. A single center experience of methotrexate in the treatment of Crohn's disease and ulcerative colitis: a case for subcutaneous administration.
Nathan DM; Iser JH; Gibson PR
J Gastroenterol Hepatol; 2008 Jun; 23(6):954-8. PubMed ID: 17559377
[TBL] [Abstract][Full Text] [Related]
8. Unfractioned heparin in the therapy of patients with highly active inflammatory bowel disease.
Folwaczny C; Wiebecke B; Loeschke K
Am J Gastroenterol; 1999 Jun; 94(6):1551-5. PubMed ID: 10364024
[TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn's disease.
Mansfield JC; Parkes M; Hawthorne AB; Forbes A; Probert CS; Perowne RC; Cooper A; Zeldis JB; Manning DC; Hawkey CJ
Aliment Pharmacol Ther; 2007 Aug; 26(3):421-30. PubMed ID: 17635377
[TBL] [Abstract][Full Text] [Related]
10. Review article: chronic active disease and maintaining remission in Crohn's disease.
Kamm MA
Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 4():102-5. PubMed ID: 15352904
[TBL] [Abstract][Full Text] [Related]
11. [Drug treatment of chronic inflammatory bowel diseases: current status and prospects].
Seibold F; Wagner AC; Göke B
Schweiz Med Wochenschr; 2000 Feb; 130(7):222-32. PubMed ID: 10719713
[TBL] [Abstract][Full Text] [Related]
12. High-dose intravenous cyclosporine in steroid refractory attacks of inflammatory bowel disease.
Hermida-Rodriguez C; Cantero Perona J; Garcia-Valriberas R; Pajares Garcia JM; Mate-Jimenez J
Hepatogastroenterology; 1999; 46(28):2265-8. PubMed ID: 10521978
[TBL] [Abstract][Full Text] [Related]
13. Rofecoxib and early relapse of inflammatory bowel disease: an open-label trial.
Biancone L; Tosti C; Geremia A; Fina D; Petruzziello C; Emerenziani S; Pallone F
Aliment Pharmacol Ther; 2004 Apr; 19(7):755-64. PubMed ID: 15043516
[TBL] [Abstract][Full Text] [Related]
14. Granulocyteaphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study.
Domènech E; Hinojosa J; Esteve-Comas M; Gomollón F; Herrera JM; Bastida G; Obrador A; Ruiz R; Saro C; Gassull MA;
Aliment Pharmacol Ther; 2004 Dec; 20(11-12):1347-52. PubMed ID: 15606397
[TBL] [Abstract][Full Text] [Related]
15. Thalidomide for the treatment of resistant cutaneous lupus: efficacy and safety of different therapeutic regimens.
Cuadrado MJ; Karim Y; Sanna G; Smith E; Khamashta MA; Hughes GR
Am J Med; 2005 Mar; 118(3):246-50. PubMed ID: 15745722
[TBL] [Abstract][Full Text] [Related]
16. Azathioprine dose escalation in inflammatory bowel disease.
Rayner CK; Hart AL; Hayward CM; Emmanuel AV; Kamm MA
Aliment Pharmacol Ther; 2004 Jul; 20(1):65-71. PubMed ID: 15225172
[TBL] [Abstract][Full Text] [Related]
17. The state of the art in the management of inflammatory bowel disease.
Hanauer SB; Present DH
Rev Gastroenterol Disord; 2003; 3(2):81-92. PubMed ID: 12776005
[TBL] [Abstract][Full Text] [Related]
18. Management of inflammatory bowel disease in adults.
Katz JA
J Dig Dis; 2007 May; 8(2):65-71. PubMed ID: 17532817
[TBL] [Abstract][Full Text] [Related]
19. Intravenous cyclosporine for inflammatory bowel disease--safe and effective.
Chermesh I; Tamir A; Lachter J; Eliakim R
Hepatogastroenterology; 2007; 54(79):2003-6. PubMed ID: 18251148
[TBL] [Abstract][Full Text] [Related]
20. Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with Crohn's disease.
Schinzari F; Armuzzi A; De Pascalis B; Mores N; Tesauro M; Melina D; Cardillo C
Clin Pharmacol Ther; 2008 Jan; 83(1):70-6. PubMed ID: 17507924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
